Overview

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Status:
RECRUITING
Trial end date:
2027-04-06
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Junshi Bioscience Co., Ltd.
Treatments:
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Gemcitabine
Ifosfamide
Lenalidomide
Oxaliplatin
Prednisone
Rituximab
Vincristine